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Abstract Comparisons of duration of response (DoR) and
duration of clinical benefit (DoCB) within clinical trials are
prone to biases. To address these biases, we used new
methodology to prospectively analyze expected DoR and
expected DoCB. Objective response rate and clinical benefit
rate were calculated for fulvestrant 500 and 250 mg, and
used to calculate expected DoR and expected DoCB for
each dose group. The ratios for expected DoR and expected
DoCB (expected DoR500/expected DoR250 and expected
DoCB500/expected DoCB250) were then calculated, thereby
allowing statistical comparisons of these endpoints between
each arm of the COmparisoN of Faslodex In Recurrent or
Metastatic breast cancer (CONFIRM) trial. Expected DoRs
for fulvestrant 500 and 250 mg were 3.2 and 3.6 months,
respectively. The expected DoR ratio between fulvestrant
500 and 250 mg was not statistically significant (0.89; 95 %
CI, 0.48–1.67, P = 0.724). The expected DoCBs for
fulvestrant 500 and 250 mg were 9.8 and 7.2 months,
respectively. The expected DoCB ratio showed that the
expected DoCB for fulvestrant 500 mg was significantly
improved compared with the expected DoCB for fulvestrant
250 mg (1.36; 95 % CI, 1.07–1.73, P = 0.013). Analysis of
the expected DoR and expected DoCB showed fulvestrant
500 mg significantly increased expected DoCB compared
with fulvestrant 250 mg in the CONFIRM trial.
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Fulvestrant is an estrogen receptor (ER) antagonist, devoid
of agonistic properties, which exerts its effects via down-
regulation of the estrogen receptor [1, 2]. Historically,
fulvestrant 250 mg was indicated for the second-line
treatment of postmenopausal women with endocrine-sen-
sitive advanced breast cancer. However, results from sev-
eral studies suggested that a higher dose of fulvestrant
might be more efficacious in this group of patients [2–4].
The COmparisoN of Faslodex In Recurrent or Metastatic
breast cancer (CONFIRM) trial was a phase III, random-
ized, double-blind, parallel-group, multicenter study that
evaluated two different doses of fulvestrant in postmeno-
pausal women with locally advanced or metastatic
ER-positive breast cancer who had progressed or recurred
on endocrine therapy. Results from the CONFIRM trial
showed that fulvestrant 500 mg was associated with a
clinically meaningful improvement in progression-free
survival (PFS) and overall benefit:risk ratio over fulvestrant
250 mg [5]. Based on the findings from this study, fulve-
strant 500 mg is now approved by the United States [6],
Europe [7], Japan, and many other markets.
Trials investigating agents for the treatment of advanced
breast cancer use a variety of efficacy endpoints with which
to measure potential benefit. Overall survival (OS) is
generally regarded as the endpoint of choice for assessing
the efficacy of new therapies in advanced breast cancer,
and provides a clear and unbiased measure of clinical
benefit as well as ease and reliability of measurement
[8, 9]. However, this endpoint requires studies with large
patient populations as well as prolonged followup of all
patients, and consideration of this endpoint alone can delay
the evaluation of novel therapies. In addition, assessment of
OS can be confounded by factors such as crossover to active
treatment arms within a trial or post-trial treatment with
non-experimental active therapies [10]. As such, assessment
of a variety of clinical endpoints can be of benefit, allowing
a more rapid evaluation of new treatments. Indeed, end-
points such as PFS and time to progression (TTP) have been
proposed as potential surrogate endpoints for survival [11].
The primary endpoint in CONFIRM was PFS, but other
secondary endpoints included objective response rate
(ORR), clinical benefit rate (CBR), duration of response
(DoR), and duration of clinical benefit (DoCB) [5].
The proportion of patients who respond to treatment and
the DoR and DoCB for patients who respond are widely
evaluated during randomized oncology trials and are con-
sidered important clinical measures that help to determine a
drug’s therapeutic value [12, 13]. However, within a trial,
formal comparisons of DoR and DoCB between treatments
in responding patients may be prone to biases and may not
reflect actual treatment effects. In addition, conflicting
results for response rates and DoR, e.g., higher response
rate in control therapy versus longer DoR in experimental
therapy, can make assessment of preferred treatment
options difficult. As such, formal comparison of DoR and
DoCB between treatments in responding patients is cur-
rently discouraged by the European Medicines Evaluation
Agency [13, 14].
New methodology proposed by Ellis et al. enables a
formal and unbiased comparison of treatments for expected
DoR and expected DoCB across all randomized patients.
Here, by this novel methodology, we present a prospective
analysis of expected DoR and expected DoCB between




The CONFIRM trial design has been described in detail
previously [5]. In brief, CONFIRM was a randomized,
phase III, double-blind study in which two different doses
of fulvestrant (500 vs 250 mg) were evaluated in post-
menopausal patients who had either locally advanced or
metastatic ER-positive breast cancer.
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Patients who experienced relapse during or within 1 year of
completion of adjuvant endocrine therapy were eligible. For
patients who experienced relapse after more than 1 year from
completion of adjuvant endocrine therapy, or for patients with
de novo advanced disease, eligibility required previous treat-
ment with either an anti-estrogen or an aromatase inhibitor as a
first-line therapy for metastatic breast cancer. Patients had to
have measurable or evaluable disease according to Response
Evaluation Criteria In Solid Tumors (RECIST) [5, 15] although
patients with lytic or mixed bone lesions were permitted to
enter the study without evidence of measurable disease.
Eligible patients were randomly assigned 1:1 to the
following two treatment arms: fulvestrant 500 mg admin-
istered as two 5-mL intramuscular injections on days 0, 14,
and 28, and every 28 (±3) days thereafter; or fulvestrant
250 mg administered as two 5-mL intramuscular injections
(one fulvestrant and one placebo) on days 0, 14 (two pla-
cebo injections only), and 28, and every 28 (±3) days
thereafter [5].
The primary study endpoint was PFS (the time elapsing
between the date of randomization and the date of earliest
evidence of objective disease progression or death from
any cause). Secondary endpoints included ORR, CBR,
DoR, DoCB, OS, tolerability, and quality of life [5].
Definitions
In this prospective analysis, ORR and CBR were calculated
by modified RECIST (mRECIST) version 1.0 criteria. The
RECIST criteria assesses, for each patient, the percentage
reduction in tumor mass on a visit-by-visit basis over the
course of the trial according to the following definitions:
complete response (CR), defined as a disappearance of all
measurable lesions and no new lesions; partial response
(PR), defined as at least a 30 % reduction in the sum of the
longest diameter of the measurable lesions and no progres-
sion of non-target lesions and no new lesions; stable disease
(SD), defined as disease in which there is neither sufficient
shrinkage to qualify for CR or PR, nor sufficient increase to
qualify for progressive disease (PD) of measurable lesions,
and there is no progression of non-measurable lesions and no
new lesions; PD, defined as at least a 20 % increase in the
sum of the longest diameter of target lesions or the pro-
gression of non-measurable lesions or the appearance of new
lesions. Disease for which there was insufficient data to
allocate a response was defined as not evaluable (NE).
For each patient, the best overall response achieved
during the course of the trial was calculated: an objective
responder was defined as any patient who had a best overall
response of CR or PR (defined as two visit responses of CR
or PR at least 28 days apart); a clinical benefit responder
was defined as any patient who had a best overall response
of CR, PR, or SD that persisted for C24 weeks.
DoR was calculated as the time (in months) from ran-
domization to progression (or death from any cause) in
patients who had a best overall response of CR or PR. ORR
and, therefore, DoR were calculated out of all randomized
patients with measurable disease at baseline (defined as at
least one lesion that could be accurately measured in at
least one dimension of C20 mm with conventional tech-
niques or C10 mm with spiral computed tomography
scan). Patients with non-measurable disease at baseline
were not used for the calculation of DoR, as these patients
only had non-targets at baseline: it was decided prospec-
tively to assess only the non-targets for incomplete
response/SD, NE, or PD and not for CR or PR.
DoCB was calculated as the time (in months) from
randomization to progression (or death from any cause) in
patients who had a best overall response of CR, PR, or SD
of C24 weeks. CBR and, therefore, DoCB were calculated
across all randomized patients, as patients could have non-
measurable disease at baseline, but still obtain a best
overall response of SD of C24 weeks.
Derivation of the expected DoR and expected DoCB
Expected DoR and expected DoCB were calculated by the
methodology described by Ellis et al. [16]. The formula
used to derive the expected DoR is shown in the Supple-
mentary Methods; this formula was similarly used to derive
the expected DoCB.
Comparison of expected DoR and expected DoCB
between fulvestrant dose groups
The expected DoR is the product of the fraction of patients
with a response and the mean DoR in responding patients.
The following calculations were, therefore, performed to
formally compare the expected DoR for the fulvestrant
500 mg group with that for the 250 mg group:
1. Calculation of the response rate (i.e., the number of
patients who responded to each treatment divided by
the total number of patients per group) for each
fulvestrant dose group.
2. Calculation of the mean DoR and associated standard
error (SE) for each fulvestrant dose group. For these
data, the log Normal distribution was selected with
model fitting performed by means of Statistical Analysis
Software [SAS], Cary, NC, USA. For the log Normal




r^2 and the variance of the log of the mean is





¼ Var l^ð Þ þr^2Var r^ð Þþ
2r^Cov l^; r^ð Þ
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3. Multiplication of estimates obtained from the above
calculations to obtain estimates of the expected DoR
for each fulvestrant dose group.
4. Calculation of the ratio of expected DoR (i.e.
R = expected DoR500/expected DoR250) and the var-
iance of [ln(R^)].
5. Assessment of the difference between the two fulve-
strant treatment groups using





compared with a standard Normal (0,1) distribution.
Similar calculations were used to compare the expected
DoCB between fulvestrant dose groups.
Results
Summary of expected DoR
The data used to calculate ORR are shown in Table 1. The
ORRs for fulvestrant 500 and 250 mg were 13.8 % (33/
240) and 14.6 % (38/261), respectively (odds ratio [OR]
0.94; 95 % confidence interval [CI], 0.57–1.55, P = 0.795)
(evaluable for all randomized patients with measurable
disease at baseline).
For patients with an objective response, the median
DoRs from randomization for fulvestrant 500 and 250 mg
were 19.4 and 16.4 months, respectively (Fig. 1). Analysis
of DoR from the date of randomization for all patients with
measurable disease at baseline is shown in Table 2. The
mean DoRs for patients with an objective response were
23.2 and 24.5 months for fulvestrant 500 and 250 mg,
respectively. The expected DoRs for all randomized
patients with measurable disease at baseline for fulvestrant
500 and 250 mg were 3.2 and 3.6 months, respectively.
The ratio of expected DoR between the fulvestrant 500
and 250 mg dose groups favored fulvestrant 250 mg;
however, this difference was not statistically significant
(ratio of expected DoR = 0.89; 95 % CI, 0.48–1.67,
P = 0.724).
Summary of expected DoCB
The data used to calculate CBR are shown in Table 3. The
CBRs for fulvestrant 500 and 250 mg were 45.6 % (165/
362) and 39.6 % (148/374), respectively (OR 1.28; 95 %
CI, 0.95–1.71, P = 0.100) (evaluable for all randomized
patients).
For patients with clinical benefit, the median DoCB from
randomization was numerically longer for the fulvestrant









CR 4 (1.7) 1 (0.4)
PR 29 (12.1) 37 (14.2)
SD 98 (40.8) 103 (39.5)
PD 102 (42.5) 117 (44.8)
NE 7 (2.9) 3 (1.1)
Best response derived according to modified RECIST
CR complete response, NE not evaluable, PD progressive disease,
PR partial response, RECIST Response Evaluation Criteria In Solid
Tumors, SD stable disease
0.0


























































No. patients at risk
Fulvestrant 500 mg
Fulvestrant 250 mg
Fig. 1 Duration of response
from date of randomization for
patients with an objective
response (evaluable for all
randomized patients with
measurable disease at baseline).
Patients with a best objective
response of complete response
or partial response are included
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500 mg group (16.6 months) compared with the fulvestrant
250 mg group (13.9 months) (Fig. 2). The mean DoCBs for
patients with clinical benefit were 21.6 and 18.3 months for
fulvestrant 500 and 250 mg, respectively. The expected
DoCBs for all randomized patients for fulvestrant 500 and
250 mg were 9.8 and 7.2 months, respectively (Table 4).
Expected DoCB for fulvestrant 500 mg was signifi-
cantly improved compared with the expected DoCB for
fulvestrant 250 mg (ratio of expected DoCB = 1.36; 95 %
CI, 1.07–1.73, P = 0.013).
Discussion
Our analysis uses new methodology to prospectively analyze
expected DoR and expected DoCB from the CONFIRM trial
Table 3 Summary of best objective response (for calculation of
duration of percent response)





CR 4 (1.1) 1 (0.3)
PR 29 (8.0) 37 (9.9)
SD C24 weeks 132 (36.5) 110 (29.4)
SD \24 weeks 47 (13.0) 52 (13.9)
PD 140 (38.7) 167 (44.7)
NE 10 (2.8) 7 (1.9)
Best response derived according to modified RECIST
CR complete response, NE not evaluable, PD progressive disease,
PR partial response, RECIST Response Evaluation Criteria In Solid
Tumors, SD stable disease
0.0


























































No. patients at risk
Fulvestrant 500 mg
Fulvestrant 250 mg
Fig. 2 Duration of clinical
benefit in patients with clinical
benefit (evaluable for all
randomized patients). Patients
with a best objective response of
complete response, partial
response, or stable disease of
C24 weeks’ duration are
included







Response rate (%) 13.8 14.6
Mean DoRa in months (SE) 23.2 (3.4) 24.5 (4.3)
Expected DoR (months) 3.2 3.6
Ratio of expected DoR (95 % CI)b 0.89 (0.48–1.67)
P value 0.724
CI confidence interval, DoR duration of response, SE standard error
a Limited to patients with an objective response, i.e. a subset of those
randomized patients with measurable disease at baseline
b Ratios of [1 favor fulvestrant 500 mg






Response rate (%) 45.6 39.6
Mean DoCBa in months (SE) 21.6 (1.3) 18.3 (1.1)
Expected DoCB (months) 9.8 7.2
Ratio of expected
DoCB (95 % CI)b
1.36 (1.07–1.73)
P value 0.013
CI confidence interval, DoCB duration of clinical benefit, SE standard
error
a Limited to patients with clinical benefit, i.e. a subset of all ran-
domized patients
b Ratios of [1 favor fulvestrant 500 mg
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and shows that fulvestrant 500 mg is associated with a
clinically meaningful benefit over fulvestrant 250 mg, as
demonstrated by the statistically significant improvement in
expected DoCB (P = 0.013). Interestingly, although the
magnitude of the difference in median DoR is similar to the
difference in median DoCB for fulvestrant 500 mg com-
pared with fulvestrant 250 mg (3.0 and 2.7 months,
respectively), the expected DoCB analysis is statistically
significant while the expected DoR is not. This is likely due
to the larger number of patients per group with a clinical
benefit response compared with the number with an objec-
tive response, as well as the greater proportion of patients
with clinical benefit in the 500 mg group.
The evaluation of most endpoints is based on clearly
defined criteria and subgroups are predefined before ran-
domization; however, a major concern regarding the com-
parison of DoR and DoCB between two treatment groups in
a randomized trial is that these values are both post-treat-
ment outcomes, calculated using a subset of responding
patients defined post-randomization. As a result, the subset
of patients who respond in the control arm may not be
comparable, in terms of important prognostic factors, with
the subset who respond in the experimental arm. Hence,
such comparisons may be prone to biases and may not
reflect the actual treatment effects. Attempts have been
made to overcome these challenges by developing statisti-
cal models that combine the fraction of patients responding
to treatment and the DoR in responding patients. In 2007,
Ellis et al. [16–18] built on earlier work, by a more flexible
approach to estimate the expected DoR across all random-
ized patients. The Ellis methodology was used here to cal-
culate the expected DoR and expected DoCB across all
patients with measurable disease and all randomized
patients, respectively, in the CONFIRM study, rather than
the subset of responding patients. This allows a more formal
and unbiased comparison of the treatment effects for ful-
vestrant 500 versus 250 mg. The improvement in expected
DoCB reported here is, therefore, indicative of a treatment
effect in favor of fulvestrant 500 versus 250 mg, consistent
with the results from the primary CONFIRM study [5].
An example of how to interpret the results is given by
the following hypothetical scenario concerning the exper-
imental arm of a given trial: one third of patients did not
respond; one third responded for 2 months; and the
remaining third responded for 4 months. In this case, the
median DoR for patients in the experimental arm who
respond to treatment is 3 months; however, for a patient
newly randomized to the experimental arm, the expected
median DoR is 2 months (calculated as [1/3 9 0] ? [1/
3 9 2] ? [1/3 9 4]). This is a meaningful finding, as
before the patient takes the experimental treatment, the
physician will not know whether or not an individual
patient will respond.
As far as we are aware, there are no other published data
that have used this novel approach to prospectively cal-
culate expected DoR and expected DoCB and make sta-
tistical comparisons of these endpoints between the
experimental and control arms. This methodology provides
an avenue by which trials can robustly analyze and report
duration data and it may be particularly appropriate for
breast cancer trials, given the importance of disease sta-
bilization in these patients.
In conclusion, the analysis of expected DoR and
expected DoCB reported here support the primary study
conclusion that fulvestrant 500 mg provides a clinically
meaningful benefit over fulvestrant 250 mg for the treat-
ment of postmenopausal women with ER-positive
advanced breast cancer who have progressed or recurred on
endocrine therapy. In our opinion, application of this novel
methodology provides an additional efficacy endpoint
option for clinical studies where stabilization of disease is a
clinically relevant endpoint.
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